Share on StockTwits

United Therapeutics (NASDAQ:UTHR)’s share price traded down 5% during mid-day trading on Friday following insider selling activity, AnalystRatingsNetwork reports. The company traded as low as $92.53 and last traded at $92.55, with a volume of 629,690 shares. The stock had previously closed at $97.39.

Specifically, CEO Martine A. Rothblatt sold 9,066 shares of the company’s stock on the open market in a transaction dated Thursday, June 12th. The shares were sold at an average price of $98.22, for a total transaction of $890,462.52. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics in a research note on Tuesday, May 27th. They now have a $104.00 price target on the stock. Finally, analysts at Standpoint Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. They now have a $118.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. United Therapeutics presently has a consensus rating of “Hold” and an average price target of $95.93.

The stock has a 50-day moving average of $99.09 and a 200-day moving average of $99.46. The company has a market cap of $4.318 billion and a P/E ratio of 21.16.

United Therapeutics (NASDAQ:UTHR) last released its earnings data on Tuesday, April 29th. The company reported $1.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.65 by $0.12. The company had revenue of $289.40 million for the quarter, compared to the consensus estimate of $300.14 million. During the same quarter in the previous year, the company posted $1.19 earnings per share. The company’s revenue for the quarter was up 18.1% on a year-over-year basis. On average, analysts predict that United Therapeutics will post $7.77 earnings per share for the current fiscal year.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.